Multiple Myeloma International Staging System (ISS)

ورودی‌های بالینی بیمار

حداقل ۰.۱ — حداکثر ۵۰ • واحد: mg/L

حداقل ۱ — حداکثر ۶ • واحد: g/dL

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
iss stage
—امتیاز
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Stage I1–1
  • Stage II2–2
  • Stage III3–3
Direct Clinical Answer

The Multiple Myeloma International Staging System (ISS) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include serum beta2 microglobulin. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Prognosticates severity of multiple myeloma based on routinely obtained lab values including serum β2 microglobulin and albumin levels.

Clinical Indication

The Multiple Myeloma International Staging System (ISS) is indicated for bedside clinical practice to support Prognosticates severity of multiple myeloma based on routinely obtained lab values including serum β2 microglobulin and albumin levels.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Results help guide treatment intensity and prognosis counseling.

Formula & Variables:

ISS Stage determination: Stage I = β2 microglobulin <3.5 mg/L AND albumin ≥3.5 g/dL; Stage II = (β2 microglobulin <3.5 mg/L AND albumin <3.5 g/dL) OR (β2 microglobulin 3.5-5.4 mg/L); Stage III = β2 microglobulin ≥5.5 mg/L

Input Parameters

NameTypeRequiredDescription
serum_beta2_microglobulinfloatYesSerum β2 microglobulin level(mg/L)
serum_albuminfloatYesSerum albumin level(g/dL)

Score Interpretation & Guidance

RangeStageDescription
1–1Stage IBest prognosis
2–2Stage IIIntermediate prognosis
3–3Stage IIIPoorest prognosis

Evidence-Based References (EBM)

  • Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412-20. doi: 10.1200/JCO.2005.04.242.DOI: 10.1200/JCO.2005.04.242
  • Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842-54. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u.DOI: 10.1002/1097-0142(197509)36:3
  • Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267.DOI: 10.1200/JCO.2015.61.2267

Related calculators